ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma

Abstract

Our results demonstrate that STAT3 plays a key role in immunosuppression of glioma and is inhibited by ACT001. ACT001 inhibits PD-L1 transcription and modulates anti-tumor immune response in glioma bearing mice. These findings will help us to understand the mechanism of ACT001 in GBM therapy.

References 65

1. 1.

   Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res. 2017;23:6279-91.

   Not in our library10.1158/1078-0432.ccr-16-2598

2. 2.

   PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. Oncoimmunology. 2018;7:e1382792.

   Not in our library10.1080/2162402x.2017.1382792

3. 3.

   Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5:e1196310.

   Not in our library10.1080/2162402x.2016.1196310

4. 4.

   Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. Oncoimmunology. 2017;6:e1328339.

   Not in our library10.1080/2162402x.2017.1328339

5. 5.

   Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clin Cancer Res. 2016;22:1161-72.

   Not in our library10.1158/1078-0432.ccr-15-1516

6. 6.

   Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors. 2018.

   Not in our library

7. 7.

   Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 2013;18:894-905.

   Not in our library10.1016/j.drudis.2013.05.005

8. 8.

   The solution and solid state stability and excipient compatibility of parthenolide in feverfew. AAPS PharmSciTech. 2007;8:E105.

   Not in our library10.1208/pt0802043

9. 9.

   Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 2012;55:8757-69.

   Not in our library10.1021/jm301064b

10. 10.

    Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1104:29-39.

    Not in our library10.1016/j.jchromb.2018.11.004

11. 11.

    Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo. PLoS One. 2015;10:e0116202.

    Not in our library10.1371/journal.pone.0116202

12. 12.
    The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo · 2019

    Not checked
13. 13.

    ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation. J Cell Biochem. 2018.

    Not in our library10.1002/jcb.27146

14. 14.

    Dimethylaminomicheliolide ameliorates peritoneal fibrosis through the activation of autophagy. J Mol Med (Berl). 2019;97:659-74.

    Not in our library10.1007/s00109-019-01757-1

15. 15.

    Micheliolide ameliorates renal fibrosis by suppressing the Mtdh/BMP/MAPK pathway. Lab Invest. 2019.

    Not in our library10.1038/s41374-019-0245-6

16. 16.

    Micheliolide suppresses LPS-induced neuroinflammatory responses. PLoS One. 2017;12:e0186592.

    Not in our library10.1371/journal.pone.0186592

17. 17.

    Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A. 2011;108:17779-84.

    Not in our library10.1073/pnas.1108482108

18. 18.

    Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3. Theranostics. 2019;9:5478-96.

    Not in our library10.7150/thno.33444

19. 19.

    IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Theranostics. 2020;10:4088-100.

    Not in our library10.7150/thno.42416

20. 20.

    The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Mol Cell Endocrinol. 2017;451:53-65.

    Not in our library10.1016/j.mce.2017.01.004

21. 21.

    Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018.

    Not in our library10.1126/scitranslmed.aam7729

22. 22.

    Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105:20852-7.

    Not in our library10.1073/pnas.0810958105

23. 23.

    Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. Cells. 2019.

    Not in our library10.3390/cells8111398

24. 24.
    Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells · 2016

    No notice
25. 25.

    Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-71.

    Not in our library

26. 26.

    The interactome and spatial redistribution feature of Ca2+ receptor protein calmodulin reveals a novel role in invadopodia-mediated invasion. Cell Death Dis. 2018;9:292.

    Not in our library10.1038/s41419-017-0253-7

27. 27.
    A reproducible brain tumour model established from human glioblastoma biopsies · 2009

    Not checked
28. 28.

    PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Lett. 2019;443:91-107.

    Not in our library10.1016/j.canlet.2018.11.034

29. 29.

    Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia. J Med Chem. 2018;61:4155-64.

    Not in our library10.1021/acs.jmedchem.8b00241

30. 30.

    The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics. 2018;8:1540-57.

    Not in our library10.7150/thno.22952

31. 31.

    Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343-9.

    Not in our library10.1016/j.ijrobp.2012.12.025

32. 32.

    Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018;33:152.

    Not in our library10.1016/j.ccell.2017.12.012

33. 33.

    Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.

    Not in our library10.1016/j.ccr.2009.12.020

34. 34.

    Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069-86.

    Not in our library10.1158/2159-8290.cd-18-0367

35. 35.

    Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86:2226-34.

    Not in our library10.1212/wnl.0000000000002770

36. 36.

    TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res. 2015;75:5273-82.

    Not in our library10.1158/0008-5472.can-15-0894

37. 37.

    Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

    Not in our library10.1038/ncomms3612

38. 38.

    Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453-7.

    Not in our library10.1038/nmeth.3337

39. 39.

    Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res. 2015;166:384-98.

    Not in our library10.1016/j.trsl.2015.03.002

40. 40.

    Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget. 2017;8:96970-83.

    Not in our library10.18632/oncotarget.18859

Cited by papers we hold 1

• ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.